Mural Oncology Primed For IL-2 Readouts Next Year
CEO Caroline Loew Outlined Firm’s Business Strategy
Executive Summary
The company, which Alkermes spun out last year, is now positioned as a pure-play oncology specialist with a focus on cytokines.